RU99112575A - DERIVATIVES OF DI- OR TRIAZA-SPIRO [4,5] DEAN - Google Patents
DERIVATIVES OF DI- OR TRIAZA-SPIRO [4,5] DEANInfo
- Publication number
- RU99112575A RU99112575A RU99112575/04A RU99112575A RU99112575A RU 99112575 A RU99112575 A RU 99112575A RU 99112575/04 A RU99112575/04 A RU 99112575/04A RU 99112575 A RU99112575 A RU 99112575A RU 99112575 A RU99112575 A RU 99112575A
- Authority
- RU
- Russia
- Prior art keywords
- phenyl
- diazaspiro
- decan
- lower alkyl
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims 13
- 125000000217 alkyl group Chemical group 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 208000002193 Pain Diseases 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- -1 decahydroazulen-2-yl Chemical group 0.000 claims 4
- 229940079593 drugs Drugs 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- NAHHRKMDRMCARX-UHFFFAOYSA-N 8-(1,2,3,4,4a,5,6,7,8,8a-decahydronaphthalen-2-yl)-1-phenyl-1,8-diazaspiro[4.5]decan-4-ol Chemical compound C1CN(C2CC3CCCCC3CC2)CCC11C(O)CCN1C1=CC=CC=C1 NAHHRKMDRMCARX-UHFFFAOYSA-N 0.000 claims 2
- 208000005298 Acute Pain Diseases 0.000 claims 2
- 206010001897 Alzheimer's disease Diseases 0.000 claims 2
- 208000000044 Amnesia Diseases 0.000 claims 2
- 206010002855 Anxiety Diseases 0.000 claims 2
- 206010057666 Anxiety disease Diseases 0.000 claims 2
- 208000000094 Chronic Pain Diseases 0.000 claims 2
- 206010010904 Convulsion Diseases 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- 206010015037 Epilepsy Diseases 0.000 claims 2
- 230000036826 Excretion Effects 0.000 claims 2
- 206010022114 Injury Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 238000006243 chemical reaction Methods 0.000 claims 2
- 230000036461 convulsion Effects 0.000 claims 2
- 230000029142 excretion Effects 0.000 claims 2
- 230000003340 mental Effects 0.000 claims 2
- 230000000926 neurological Effects 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- UBBZCMHYEXFQLP-UHFFFAOYSA-N 8-(1,2,3,3a,4,5,6,7,8,8a-decahydroazulen-2-yl)-1-phenyl-1,8-diazaspiro[4.5]decan-4-ol Chemical compound C1CN(C2CC3CCCCCC3C2)CCC11C(O)CCN1C1=CC=CC=C1 UBBZCMHYEXFQLP-UHFFFAOYSA-N 0.000 claims 1
- HLTDFERUYLFCNZ-UHFFFAOYSA-N 8-(2,3,3a,4,5,6,7,7a-octahydro-1H-inden-2-yl)-4-methoxy-1-phenyl-1,8-diazaspiro[4.5]decane Chemical compound C1CN(C2CC3CCCCC3C2)CCC11C(OC)CCN1C1=CC=CC=C1 HLTDFERUYLFCNZ-UHFFFAOYSA-N 0.000 claims 1
- QHTQYPKXERQNOC-UHFFFAOYSA-N 8-(4-methyl-2,3-dihydro-1H-inden-2-yl)-1-phenyl-1,8-diazaspiro[4.5]decan-4-ol Chemical compound C1C=2C(C)=CC=CC=2CC1N(CC1)CCC21C(O)CCN2C1=CC=CC=C1 QHTQYPKXERQNOC-UHFFFAOYSA-N 0.000 claims 1
- GGHCQCPBCWGMLS-UHFFFAOYSA-N 8-cyclononyl-1-phenyl-1,8-diazaspiro[4.5]decan-4-ol Chemical compound C1CN(C2CCCCCCCC2)CCC11C(O)CCN1C1=CC=CC=C1 GGHCQCPBCWGMLS-UHFFFAOYSA-N 0.000 claims 1
- 206010005742 Blood pressure disorder Diseases 0.000 claims 1
- GSLQFTDIDMAQFF-TYABSZSSSA-N C1CN([C@H]2CC[C@H](CC2)C(C)C)CCC11C(OC)CCN1C1=CC=CC=C1 Chemical compound C1CN([C@H]2CC[C@H](CC2)C(C)C)CCC11C(OC)CCN1C1=CC=CC=C1 GSLQFTDIDMAQFF-TYABSZSSSA-N 0.000 claims 1
- PYLMXMMNCOOKBN-BGYRXZFFSA-N C1C[C@@H](C(C)C)CC[C@H]1N1CCC2(C(CCN2C=2C=CC=CC=2)=O)CC1 Chemical compound C1C[C@@H](C(C)C)CC[C@H]1N1CCC2(C(CCN2C=2C=CC=CC=2)=O)CC1 PYLMXMMNCOOKBN-BGYRXZFFSA-N 0.000 claims 1
- ONQCLUYDCHVQHC-RLAPIPATSA-N C1C[C@@H](C(C)C)CC[C@H]1N1CCC2(N(CCC2O)C=2C=CC=CC=2)CC1 Chemical compound C1C[C@@H](C(C)C)CC[C@H]1N1CCC2(N(CCC2O)C=2C=CC=CC=2)CC1 ONQCLUYDCHVQHC-RLAPIPATSA-N 0.000 claims 1
- ONQCLUYDCHVQHC-VWPQPMDRSA-N C1C[C@@H](C(C)C)CC[C@H]1N1CCC2(N(CC[C@@H]2O)C=2C=CC=CC=2)CC1 Chemical compound C1C[C@@H](C(C)C)CC[C@H]1N1CCC2(N(CC[C@@H]2O)C=2C=CC=CC=2)CC1 ONQCLUYDCHVQHC-VWPQPMDRSA-N 0.000 claims 1
- ONQCLUYDCHVQHC-RZUBCFFCSA-N C1C[C@@H](C(C)C)CC[C@H]1N1CCC2(N(CC[C@H]2O)C=2C=CC=CC=2)CC1 Chemical compound C1C[C@@H](C(C)C)CC[C@H]1N1CCC2(N(CC[C@H]2O)C=2C=CC=CC=2)CC1 ONQCLUYDCHVQHC-RZUBCFFCSA-N 0.000 claims 1
- 208000008466 Metabolic Disease Diseases 0.000 claims 1
- 230000036740 Metabolism Effects 0.000 claims 1
- PULGYDLMFSFVBL-SMFNREODSA-N Nociceptin Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)[C@@H](C)O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 PULGYDLMFSFVBL-SMFNREODSA-N 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 230000036772 blood pressure Effects 0.000 claims 1
- 230000000875 corresponding Effects 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- DTDMYWXTWWFLGJ-UHFFFAOYSA-N decan-4-ol Chemical compound CCCCCCC(O)CCC DTDMYWXTWWFLGJ-UHFFFAOYSA-N 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- BNRNAKTVFSZAFA-UHFFFAOYSA-N hydrindane Chemical compound C1CCCC2CCCC21 BNRNAKTVFSZAFA-UHFFFAOYSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 230000001771 impaired Effects 0.000 claims 1
- 125000004129 indan-1-yl group Chemical group [H]C1=C([H])C([H])=C2C(=C1[H])C([H])([H])C([H])([H])C2([H])* 0.000 claims 1
- 125000004130 indan-2-yl group Chemical group [H]C1=C([H])C([H])=C2C(=C1[H])C([H])([H])C([H])(*)C2([H])[H] 0.000 claims 1
- 231100000863 loss of memory Toxicity 0.000 claims 1
- 230000004060 metabolic process Effects 0.000 claims 1
- 230000035786 metabolism Effects 0.000 claims 1
- 230000003533 narcotic Effects 0.000 claims 1
- 102400001111 nociceptin Human genes 0.000 claims 1
- 108090000622 nociceptin Proteins 0.000 claims 1
- 102000029985 nociceptin receptor Human genes 0.000 claims 1
- 108010020615 nociceptin receptor Proteins 0.000 claims 1
- 239000000546 pharmaceutic aid Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 238000006268 reductive amination reaction Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
Claims (11)
где R1 означает C6-10циклоалкил, необязательно замещенный низшим алкилом или C(O)O-низшим алкилом, декагидронафталин-1-ил, декагидронафталин-2-ил, индан-1-ил или индан-2-ил, необязательно замещенные низшим алкилом, декагидроазулен-2-ил, бицикло[6.2.0]дец-9-ил, аценафтен-1-ил, 2,3-дигидро-1Н-фенален-1-ил, 2,3,3а,4,5,6-гексагидро-1Н-фенален-1-ил или октагидроинден-2-ил;
R2 означает водород, низший алкил, =O или фенил, необязательно замещенный низшим алкилом, галогеном или алкоксигруппой,
означает циклогексил или фенил, необязательно замещенный низшим алкилом, галогеном или алкоксигруппой;
X означает -CH(OH)-, -C(O)-, -CHR3-, -CR3=, -O-, -S-, -CH(COOR4)- или -(COOR4)=;
Y означает -CH2-, -CH=, -CH(COOR4)-, -C(COOR4)=, -C(CN)- или -N=;
R3 означает водород или низшую алкоксигруппу;
R4 означает низший алкил, циклоалкил, фенил или бензил и либо а, либо b может обозначать необязательную дополнительную химическую связь,
рацемические смеси и их соответствующие энантиомеры, а также фармацевтически приемлемые кислотно-аддитивные соли указанных соединений.1. Compounds of General Formula I
where R 1 means C 6-10 cycloalkyl, optionally substituted lower alkyl or C (O) O-lower alkyl, decahydronaphthalen-1-yl, decahydronaphthalen-2-yl, indan-1-yl or indan-2-yl, optionally substituted lower alkyl, decahydroazulen-2-yl, bicyclo [6.2.0] dec-9-yl, acenaphene-1-yl, 2,3-dihydro-1H-phenylene-1-yl, 2,3,3a, 4,5 6-hexahydro-1H-phenanen-1-yl or octahydroinden-2-yl;
R 2 means hydrogen, lower alkyl, = O or phenyl, optionally substituted by lower alkyl, halogen or alkoxygroup,
means cyclohexyl or phenyl, optionally substituted with lower alkyl, halogen, or alkoxy;
X is -CH (OH) -, -C (O) -, -CHR 3 -, -CR 3 =, -O-, -S-, -CH (COOR 4 ) - or - (COOR 4 ) =;
Y means -CH 2 -, -CH =, -CH (COOR 4 ) -, -C (COOR 4 ) =, -C (CN) - or -N =;
R 3 is hydrogen or lower alkoxy;
R 4 means lower alkyl, cycloalkyl, phenyl or benzyl and either a or b may indicate an optional additional chemical bond,
racemic mixtures and their corresponding enantiomers, as well as pharmaceutically acceptable acid addition salts of these compounds.
(R)-8-(цис-4-изопропилциклогексил)-1-фенил-1,8-диазаспиро[4,5] декан-4-ол,
(S)-8-(цис-4-изопропилциклогексил)-1-фенил-1,8-диазаспиро[4,5] декан-4-ол,
8-(цис-4-изопропилциклогексил)-1-фенил-1,8-диазаспиро[4,5]декан-4-он,
(RS)-8-(цис-4-изопропилциклогексил)-4-метокси-1-фенил-1,8-диазаспиро[4,5]декан или
(RS)-8-циклононил-1-фенил-1,8-диазаспиро[4,5]декан-4-ол.3. The compound according to claim 2, selected from the group including (RS) -8- (cis-4-isopropylcyclohexyl) -1-phenyl-1,8-diazaspiro [4,5] decan-4-ol,
(R) -8- (cis-4-isopropylcyclohexyl) -1-phenyl-1,8-diazaspiro [4,5] decan-4-ol,
(S) -8- (cis-4-isopropylcyclohexyl) -1-phenyl-1,8-diazaspiro [4,5] decan-4-ol,
8- (cis-4-isopropylcyclohexyl) -1-phenyl-1,8-diazaspiro [4,5] decan-4-one,
(RS) -8- (cis-4-isopropylcyclohexyl) -4-methoxy-1-phenyl-1,8-diazaspiro [4,5] decane or
(RS) -8-cyclononyl-1-phenyl-1,8-diazaspiro [4,5] decan-4-ol.
(RS)- и (SR)-8-[(2RS, 4аSR,8аRS)-декагидронафталин-2-ил]-1-фенил-1,8-диазаспиро[4,5]декан-4-ол,
8-(декагидронафталин-2-ил)-1-фенил-1,8-диазаспиро[4,5]декан-4-ол,
8-(2,3,3а, 4,5,6-гексагидро-1Н-фенален-1-ил)-1-фенил-1,8-диазаспиро[4,5] декан-4-ол,
(RS)- и (SR)-8-[(RS)-(4-метилиндан-2-ил)] -1-фенил-1,8-диазаспиро[4,5] декан-4-ол,
8-(декагидроазулен-2-ил)-1-фенил-1,8-диазаспиро[4,5]декан-4-ол или
8-(октагидроинден-2-ил)-4-метокси-1-фенил-1,8-диазаспиро[4,5] декан (смесь диастереоизомеров).5. The compound according to claim 4, selected from the group including
(RS) - and (SR) -8 - [(2RS, 4aSR, 8aRS) -decahydronaphthalen-2-yl] -1-phenyl-1,8-diazaspiro [4,5] decan-4-ol,
8- (decahydronaphthalen-2-yl) -1-phenyl-1,8-diazaspiro [4,5] decan-4-ol,
8- (2,3,3a, 4,5,6-hexahydro-1H-phenan-1-yl) -1-phenyl-1,8-diazaspiro [4,5] decan-4-ol,
(RS) - and (SR) -8 - [(RS) - (4-methylindan-2-yl)] -1-phenyl-1,8-diazaspiro [4,5] decan-4-ol,
8- (decahydroazulen-2-yl) -1-phenyl-1,8-diazaspiro [4,5] decan-4-ol or
8- (octahydroinden-2-yl) -4-methoxy-1-phenyl-1,8-diazaspiro [4,5] decane (mixture of diastereoisomers).
соединением формулы
где имеют значения, указанные выше, и при необходимости превращение рацемической смеси в энантиомеры и/или превращение полученных соединений в фармацевтически приемлемую кислотно-аддитивную соль.8. The method of obtaining the compounds of formula I according to claim 1, which includes reductive amination of the compounds of formula
compound of formula
Where have the meanings indicated above, and if necessary, the conversion of the racemic mixture into enantiomers and / or the conversion of the compounds obtained into a pharmaceutically acceptable acid addition salt.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP98110803.8 | 1998-06-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
RU99112575A true RU99112575A (en) | 2001-04-27 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5094720B2 (en) | How to treat substance-related disorders | |
ES2313187T3 (en) | FORMULATION OF EXO-S-MECAMILAMINE. | |
JP2632754B2 (en) | Brain glutamate release inhibitor | |
EP2258372B1 (en) | A2A antagonists for use in the treatment of motor disorders | |
US20240197681A1 (en) | Methods and compositions relating to psychedelics and serotonin receptor modulators | |
TWI582092B (en) | Cis-tetrahydro-spiro(cyclohexane-1,1'-pyrido[3,4-b]indole)-4-amine derivatives | |
RU96118132A (en) | COMPOUNDS ACTIVE IN THE NEW SITE ON THE RECEPTOR-REGULATED CALCIUM CHANNELS AND USED FOR TREATMENT OF NEUROLOGICAL DISORDERS AND DISEASES | |
RU98114683A (en) | 5-H-THIAZOLE [3,2-A] PYRIMIDINE DERIVATIVES | |
WO1993006826A1 (en) | Composition comprising s-oxiracetame for use as nootropic | |
JP2930245B2 (en) | 1,2,3,4-tetrahydro-9-acridinamine derivatives | |
JP2002544232A (en) | Method for producing and using N-desmethylzopiclone | |
JP2002518442A (en) | Use of valproic acid analogs for the treatment and prevention of migraine and affective illness | |
CN100398154C (en) | Remedies for psychoneurosis | |
Lawrence et al. | The use of choline chloride in ataxic disorders. | |
CA2274201A1 (en) | Di-or triaza-spiro[4,5]decane derivatives | |
RU2004131214A (en) | METHODS FOR TREATING COGNITIVE DISORDERS | |
US9192605B2 (en) | Compositions and methods for treating parkinson's disease | |
RU99112575A (en) | DERIVATIVES OF DI- OR TRIAZA-SPIRO [4,5] DEAN | |
HUP9901909A2 (en) | Spiro piperidine-4,1'-pyrrolo[3,4-c]pyrrole derivatives as agonist and/or antagonist of the orphanin fq(ofq)receptor, preparation and use thereof | |
SK1912004A3 (en) | Nicotinic acetylcholine receptor agonists in the treatment of restless legs syndrome | |
JP2023510865A (en) | Composition for the treatment of angiolipoma | |
RU2006128613A (en) | DIAZASPIROPIPERIDINE DERIVATIVES | |
RU2005141307A (en) | DERIVATIVES OF BENZOTIAZOZOLES AND THEIR APPLICATION FOR TREATMENT OF DISEASES CONNECTED WITH Adenosine A2A-RECEPTORS | |
RU99112574A (en) | DERIVATIVES OF DIAZA-SPIRO [3,5] NONANA | |
WO1999056750A1 (en) | Use of 4-piperidinemethanol derivatives in treatment of neurodevelopmental disorders |